United Therapeutics Corp. Hits New 52-Week High of $479.50

United Therapeutics Corp. has reached a significant milestone by hitting a new 52-week high of USD 479.50 on October 29, 2025. This achievement underscores the company's robust performance in the pharmaceuticals and biotechnology sector, where it operates as a mid-cap entity with a market capitalization of USD 28,352 million.
Over the past year, United Therapeutics has demonstrated impressive growth, with a remarkable 65.42% increase in stock price, significantly outperforming the S&P 500's 18.33% gain during the same period. The company's strong fundamentals are reflected in its return on equity (ROE) of 17.59%, indicating effective management and operational efficiency.

Additionally, United Therapeutics boasts a low debt-to-equity ratio of -0.42, highlighting its financial stability. The company has consistently reported positive results for the last eight consecutive quarters, with operating cash flow reaching a peak of USD 1,368.6 million. This performance is complemented by a price-to-book ratio of 3.95, suggesting an attractive valuation relative to its peers.

As United Therapeutics continues to solidify its position in the market, this new high marks a noteworthy achievement in its ongoing growth trajectory.